PARK7/DJ1 anticorps (C-Term)

N° du produit ABIN374310

Cet anticorps anti-PARK7/DJ1 Polyclonal Chèvre (ABIN374310) détecte spécifiquement PARK7/DJ1 dans WB et EIA. L’anticorps est réactif avec des échantillons de Humain, Souris et Rat.

Aperçu rapide pour PARK7/DJ1 anticorps (C-Term) (ABIN374310)

Antigène: PARK7/DJ1 (PARK7) (Parkinson Protein 7 (PARK7))

Reactivité: Humain, Souris, Rat

Hôte: Chèvre

Clonalité: Polyclonal

Conjugué: Cet anticorp PARK7/DJ1 est non-conjugé

Application: Western Blotting (WB), Enzyme Immunoassay (EIA)

Détail du produit anti-PARK7/DJ1 anticorps

Épitope: C-Term

Séquence: C-AAQVKAPLVL KD

Specificité: This antibody detects DJ-1 / PARK7 at C-term.

Réactivité croisée (Details): Species reactivity (expected):Mouse, Rat.
Species reactivity (tested):Human.

Purification: Ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide

Immunogène: Peptide from C Terminus of the protein sequence according to NP_001116849.1, NP_009193.2 Genename: PARK7

Information d'application

Indications d'application: Peptide ELISA: Limit dilution 1: 32000. Western blot: 0.5-1 μg/mL. Approx 20 kDa band seen in Jurkat lysate [Predicted MW ofapprox.20 kDa according to NP_009193].
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Restrictions: For Research Use only

Stockage

Concentration: 0.5 mg/mL

Buffer: Tris saline, 0.02 % sodium azide, pH 7.3 with 0.5 % bovine serum albumin

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: Avoid repeated freezing and thawing.

Stock: 4 °C/-20 °C

Stockage commentaire: Store at 2 - 8 °C for up to one month or (in aliquots) at -20 °C.

Détails sur PARK7/DJ1

Antigène: PARK7/DJ1 (PARK7) (Parkinson Protein 7 (PARK7))

Autre désignation: DJ-1 / PARK7

Sujet: PARK7/DJ1 is a ubiquitously expressed protein involved in various cellular processes including cell proliferation, RNA-binding, and oxidative stress. The protein has been found to colocalize within a subset of pathologic tau inclusions in a diverse group of neurodegenerative disorders known as tauopathies (Rizzu et al. 2004). Defects in PARK7/DJ1 are the cause of autosomal recessive early-onset Parkinson's disease 7 (PARK7). Parkinson's disease (PD) is a complex, multifactorial disorder that typically manifests after the age of 50 years. The disease is characterized by bradykinesia, resting tremor, muscular rigidity and postural instability. The pathology involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. PARK7 is characterized by onset before 40 years and slow progression. It has also been suggested that PARK7/DJ1 is a mitogen dependent oncogene product involved in Ras related signal transduction pathways.Synonyms: Oncogene DJ1, Parkinson disease protein 7

ID gène: 11315

NCBI Accession: NP_001116849

UniProt: Q99497

Pathways: Intracellular Steroid Hormone Receptor Signaling Pathway, Regulation of Intracellular Steroid Hormone Receptor Signaling, Proton Transport